Interview with Philippe Ranty, Managing Director, Actavis France
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
Address: 14 ave Duquesne, 75007 Paris,France
Tel: 01 40 56 60 65
Web: http://www.sante.gouv.fr/
The Committee Economic Health Products (CEPS) replaced the previous Economic Committee of drugs in 2000. Its missions have been extended to cover health products and services associated with refundable in addition to drugs and it has been amended accordingly.
CEPS contributes to the development of drug policy by putting into practice advice it receives from relevant ministers, applying it notably to price fixing with respect to expenditure and financial regulation of the market. In order to carry this out, the CEPS reaches agreements with businesses on relevant topics, such as drug prices, price evolution, drug reimbursements, regulations concerning the proper use of drugs and sales volumes, as well as methods of participation of enterprises in the implementation of departmental policies.
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
CIP and GERS have very unique relationships with the pharmaceutical industry. Could you elaborate on the role of these two bodies? Club Inter-pharmaceutique (CIP) is a professional association created in…
As a majority of our readers are American that may be used to a different model of clusters can you explain the unique characteristics of the pôles de compétitivité? The…
Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is Eisai in France…
There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these…
As president of LEEM, what will be your legacy and what legacy would you like to instill in the organization? A legacy of re-industrialization in the French pharmaceutical and health…
Roche has a long history in France and currently enjoys a higher position than its worldwide ranking. Can you elaborate on the importance of this market for the group overall?…
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a…
France yet today you work for a foreign multinational within France. Can you speak to the differences in culture and what the transition has been like? I have spent half…
The French President declared that he intended to make France the most welcoming and attractive place for the healthcare industry. Do you think this is possible? Can France be the…
See our Cookie Privacy Policy Here
